Saturday, March 21, 2026

Artifacts From NASA’s Webb, Parker Solar Probe on View at Smithsonian - NASA

NASA’s James Webb Space Telescope Optical Telescope Element Pathfinder testing hardware, and a full-scale model of Parker Solar Probe are now on display inside the Smithsonian's National Air and Space Museum, Steven F. Udvar-Hazy Center in Chantilly, Virginia.

Credit: Smithsonian’s National Air and Space Museum

A testing replica of the “backbone” of NASA’s James Webb Space Telescope and a full-scale model of the agency’s Parker Solar Probe are now on permanent display at the Smithsonian’s National Air and Space Museum, Steven F. Udvar-Hazy Center in Chantilly, Virginia.

“From touching the Sun with Parker Solar Probe to creating humanity’s most powerful window into the cosmos with the James Webb Space Telescope, these missions show what humanity can achieve as we continue to push the boundaries of human knowledge through visionary science,” said Nicky Fox, associate administrator, Science Mission Directorate, NASA Headquarters in Washington. “It’s not just the iconic hardware from these NASA missions on display — it’s the courage, skill, and ingenuity of the scientists, engineers, and teams who dared to turn the nearly impossible into reality.” 

Joining other historic NASA missions like Apollo, Voyager, and the Discovery Space Shuttle, Webb’s Optical Telescope Element Pathfinder has made its way to the Steven F. Udvar-Hazy Smithsonian museum for permanent display. The Pathfinder is the largest intact mirror support structure of its kind, comprised of exotic lightweight materials invented for the purpose of seeing near to the very limits of the observable universe. This unique piece of hardware served a critical role in ensuring mission success by enabling engineers to build a comprehensive testing program to validate and ensure the most complicated optical system ever built would work flawlessly after launch.
Credits: Producer/Writer: Thaddeus Cesari; Editor: Paul Morris; Images: NASA, ESA, CSA, STScI
Music Credit: “History in Motion” by Fred Dubois [SACEM], Koka Media [SACEM], Universal Publishing Production Music France [SACEM], and Universal Production Music.

Webb’s Optical Telescope Element Pathfinder is the largest intact mirror support structure of its kind, standing over 21 feet tall, with a secondary mirror that when fully deployed reaches more than 26 feet. This pathfinder was constructed as a high-fidelity telescope nearly identical to Webb, the largest and most powerful space telescope ever built. Webb’s science goals required an exceptionally precise mirror, too large to fit fully deployed in any available rocket. The mission’s enormous size, complexity, and extreme temperature requirements demanded a comprehensive rethinking of how to test a spacecraft for the rigors of spaceflight. The pathfinder served a key role in surmounting these challenges.

NASA's James Webb Telescope Optical Telescope Element pathfinder backdropped by the Discovery Space Shuttle inside the Smithsonian's National Air and Space Museum, Steven F. Udvar-Hazy Center in Chantilly, Virginia.

Credit: Smithsonian’s National Air and Space Museum

“NASA is proud to see the James Webb Space Telescope Optical Telescope Element Pathfinder on display at the Smithsonian’s Udvar-Hazy Center,” said Mike Davis, NASA’s project manager for the Webb telescope at the agency’s Goddard Space Flight Center in Greenbelt, Maryland. “This remarkable test structure helped engineers prepare the largest space telescope ever built. Standing before it, visitors can glimpse not only the immense scale of Webb, but also the human curiosity and ingenuity that drive us to reach beyond our world and explore the universe.”

Joining the Webb pathfinder on display is a replica of NASA’s Parker Solar Probe. Built and operated at the Johns Hopkins Applied Physics Laboratory (APL) in Laurel, Maryland, Parker is more than seven years into its daring mission, with numerous successful encounters bringing the spacecraft just 3.8 million miles from the solar surface at a blazing 430,000 mph — faster and closer than any spacecraft in history. Despite brutal temperatures and radiation conditions, Parker Solar Probe has completed 27 of these close approaches to collect unprecedented data from the only star we can study up close. The replica allows visitors insight into the innovative technology behind the spacecraft’s ability to survive and successfully sample the Sun’s super-heated outer atmosphere.

Also built at APL, the Parker replica stands 10 feet high, 21.5 feet long, and 8.5 feet wide and includes several of the mission’s spare parts. Several of the components are exact duplicates of the hardware now in space, built to be swapped if flight hardware failed in prelaunch testing. These components include the heat shield that protects the probe from temperatures nearing 2,000 Fahrenheit and a camera called WISPR (the Wide-Field Imager for Solar Probe) that views and records the Sun’s activity just off the surface. The model also includes a copy of the solar array cooling system that circulates water through solar panels to survive the Sun in close approaches.

A full-scale model of Parker Solar Probe now hangs from the ceiling at the Smithsonian's National Air and Space Museum, Steven F. Udvar-Hazy Center.

Credit: Smithsonian's National Air and Space Museum

“Parker Solar Probe has been vital for giving us an up-close look at one of the most extreme environments in our solar system, showing us where space weather is born,” said Adam Szabo, Parker Solar Probe mission scientist at NASA Goddard. “This information is key to understanding the Sun’s upper atmosphere and how it affects us.”

The James Webb Space Telescope is the world’s premier space science observatory. Webb is solving mysteries in our solar system, looking beyond to distant worlds around other stars, and probing the mysterious structures and origins of our universe and our place in it. Webb is an international program led by NASA with its partners, ESA (European Space Agency) and CSA (Canadian Space Agency).

Parker Solar Probe was developed as a part of NASA’s Living With a Star (LWS) program to explore aspects of the Sun-Earth system that directly affect life and society. The LWS program is managed by the agency’s Goddard Space Flight Center in Greenbelt, Maryland, for NASA’s Science Mission Directorate in Washington. Johns Hopkins APL manages Parker Solar Probe for NASA and designed, built, and operates the mission.

To learn more about NASA’s science missions, visit: https://science.nasa.gov

By Thaddeus Cesari, Desiree Apodaca
NASA’s Goddard Space Flight Center, Greenbelt, Md.
 

Source: Artifacts From NASA’s Webb, Parker Solar Probe on View at Smithsonian - NASA Science

Combination treatment benefits patients with advanced breast cancer that has spread to the brain - medicalxpress

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

The Phase II study, published today in Nature Cancer, included 17 female patients with newly diagnosed LM and HER2+ breast cancer. Median overall survival (OS) in those treated with the combination therapy increased from a historical average of 4.4 months to 10 months. At the 18-month mark, 41% of patients were still alive. Under the combination treatment, disease progression also stalled, with a median of seven months before central nervous system progression, and 7 of 12 evaluable patients also had improved neurologic deficits.

"The combination achieved a clinically meaningful improvement in overall survival compared to historical controls," said lead author Rashmi Murthy, M.D., associate professor of Breast Medical Oncology. "For these patients, who often face limited treatment options, our results represent a step forward, offering new hope in how we treat and manage leptomeningeal metastasis."

Limited treatments for patients with leptomeningeal metastasis

Leptomeningeal metastasis is difficult to treat primarily because the blood-brain barrier may block drugs from reaching the spinal fluid, where the metastatic cells are found. Additionally, LM is not a solid tumor but is made up of metastatic cells living in fluid, making them more difficult to target. Historically, there also are few studies about this specific disease.

"In addition to encouraging survival outcomes, throughout this study we observed improvements in neurologic symptoms," said co-lead author Barbara O'Brien, M.D., associate professor of Neuro-Oncology. "Treatments for breast cancer leptomeningeal metastasis have historically focused on stabilizing disease rather than improving symptoms, making these findings particularly meaningful and encouraging."

How the combination therapy works

Tucatinib is a targeted therapy pill that blocks the HER2 protein, which helps some breast cancers grow. Trastuzumab is a targeted antibody that attaches to the HER2 protein on cancer cells and helps the immune system destroy them. Finally, capecitabine is a chemotherapy pill that turns into 5-fluorouracil (5-FU) in the body to eliminate fast-growing cancer cells.

The single-arm, nonrandomized, multiphase study enrolled patients at four sites in the U.S., including UT MD Anderson. Eligible patients were at least 18 years old with histologically proven metastatic HER2+ breast carcinoma. These patients were treated with 21-day cycles of oral tucatinib (300 mg) twice daily, plus oral capecitabine (1,000 mg/m2) twice daily on days 1–14 and intravenous trastuzumab (6 mg/kg) on day 21.

Other key findings

Side effects included diarrhea, nausea, vomiting, hand-foot syndrome, and liver function test elevation. Most adverse effects improved or resolved with appropriate care and dose modifications. One patient saw alanine aminotransferase elevation after one cycle, which led to discontinuation of the combination, and symptoms resolved after one month.

Study limitations include early termination due to slow accrual following Food & Drug Administration (FDA) approval of the combination therapy. Additionally, LM from HER2+ metastatic breast cancer is rare, resulting in limited published data. As a result, the study design was informed by the small amount of available retrospective evidence. 

Source: Combination treatment benefits patients with advanced breast cancer that has spread to the brain